Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: Mol Pharm. 2019 Jun 27;16(8):3534–3543. doi: 10.1021/acs.molpharmaceut.9b00369

Figure 4.

Figure 4

Plasma concentrations versus time curves following a single 3 mg/kg IP dose of TfRMAb-EPO (n=3) or TfRMAb-N292G-EPO (n=3) expressed as either (A, C) µg/mL or (B, D) %ID/mL. Data are shown as Mean ± SEM.